THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, January 17, 2025
PV departments have excelled in operational efficiency, employing intelligent IT solutions and outsourcing for cost-effective and streamlined case management. Yet, the predominant focus on efficacy in drug development and organizational structures may overlook the strategic importance of safety.
Fremont, CA: The development of COVID-19 vaccines during the pandemic has highlighted a shift in the types of medicines being developed and the need for effective stakeholder management for their successful adoption. However, amidst this evolution, the fundamental importance of evaluating the safety and efficacy of medications remains unchanged. The changing landscape calls for new skills in assessing medicine safety and managing the diverse entities involved, facilitated by therapeutic advancements, digitalization, enhanced technology, data accessibility, and a patient-centered approach.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The Crucial Role of Pharmacovigilance (PV) in Drug Development:
Since the thalidomide tragedy in the early 1960s, ensuring the safety and efficacy of medications has been a paramount concern, leading to the establishment of various disciplines and regulatory frameworks to safeguard public health. Regulatory authorities oversee drug approval, licensing, and usage, ensuring adherence to laws and ethical principles. Protecting public health and patient safety remains the foremost priority when administering medications and vaccines.
Conversely, PV—focused on studying adverse effects of medications and vaccines—has gained prominence amid debates over the safety of COVID-19 vaccines. This discourse has thrust PV into controversial and political debates, fueling opposition to certain vaccines and vaccine hesitancy among some populations.
Presently, discussions surrounding medication development often prioritize treatment efficacy over safety considerations. However, regulatory requirements mandate the reporting of adverse events and drug reactions, positioning PV as a crucial data-gathering and reporting entity. PV departments have excelled in operational efficiency, employing intelligent IT solutions and outsourcing for cost-effective and streamlined case management. Yet, the predominant focus on efficacy in drug development and organizational structures may overlook the strategic importance of safety.
The Limitations of PV Automation in Addressing Ecosystem Shifts:
The COVID-19 pandemic has underscored the need for a new research and healthcare paradigm, where PV's scientific excellence must be applied thoughtfully amidst evolving medication types and approval processes. Changes in medication modalities, digitalization, innovative clinical trial designs, and regulatory complexities suggest that PV's emphasis on automation and operational excellence alone may fall short in the future.
More in News